Cargando…

Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?

As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies. Supported by rapid advances in antibody engineeri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Del Bano, Joanie, Chames, Patrick, Baty, Daniel, Kerfelec, Brigitte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698871/ https://www.ncbi.nlm.nih.gov/pubmed/31557983 http://dx.doi.org/10.3390/antib5010001

Ejemplares similares

A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer
por: Del Bano, Joanie, et al.
Publicado: (2019)

A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy
por: Turini, Marc, et al.
Publicado: (2014)

Therapeutic Antibodies for the Treatment of Pancreatic Cancer
por: Chames, Patrick, et al.
Publicado: (2010)

Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response
por: Raynaud, Adeline, et al.
Publicado: (2020)

Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies
por: Benloucif, Abdennour, et al.
Publicado: (2023)

Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
por: Blanco, Belén, et al.
Publicado: (2021)

Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy
por: Santich, Brian H., et al.
Publicado: (2020)

Bispecific antibodies come to the aid of cancer immunotherapy
por: Amelio, Ivano, et al.
Publicado: (2021)

Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
por: Zhou, Yanchen, et al.
Publicado: (2022)

A path forward to improving the specificity of immunotherapies
por: Barber, Brittany, et al.
Publicado: (2022)

Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy
por: Zhou, Shu-juan, et al.
Publicado: (2017)

Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
por: You, Gihoon, et al.
Publicado: (2021)

Antibodies for HIV prevention: the path forward
por: Malhotra, Shelly, et al.
Publicado: (2023)

Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
por: Moon, Dain, et al.
Publicado: (2022)

Bioassay Development for Bispecific Antibodies—Challenges and Opportunities
por: Register, Ames C., et al.
Publicado: (2021)

Bispecific Antibody-Bound T Cells as a Novel Anticancer Immunotherapy
por: Cho, Jaewon, et al.
Publicado: (2022)

Current landscape and future directions of bispecific antibodies in cancer immunotherapy
por: Wei, Jing, et al.
Publicado: (2022)

Bioelectronic medicine: updates, challenges and paths forward
por: Pavlov, Valentin A., et al.
Publicado: (2019)

Building Biofoundry India: challenges and path forward
por: Panda, Binay, et al.
Publicado: (2021)

Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell–Redirected Bispecific Antibodies
por: Lussana, Federico, et al.
Publicado: (2021)

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
por: Yang, Yan, et al.
Publicado: (2021)

Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question
por: Ordóñez-Reyes, Camila, et al.
Publicado: (2022)

Editorial on “Cell Therapy, Bispecific Antibodies and Other Immunotherapies against Cancer”
por: Golubovskaya, Vita
Publicado: (2023)

Current trends and challenges in the downstream purification of bispecific antibodies
por: Chen, Serene W, et al.
Publicado: (2021)

Recent advances and challenges of bispecific antibodies in solid tumors
por: Wu, Yuze, et al.
Publicado: (2021)

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
por: Middelburg, Jim, et al.
Publicado: (2021)

An industrial view on Thorium: Possibilities, Challenges and Paths forward
por: Van Der Durpel, Luc
Publicado: (2013)

The Challenges in Predicting ECMO Survival, and a Path Forward
por: Huesch, Marco, et al.
Publicado: (2017)

Multiple Hazard Uncertainty Visualization Challenges and Paths Forward
por: Padilla, Lace, et al.
Publicado: (2021)

Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer
por: Chanier, Timothée, et al.
Publicado: (2019)

A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy
por: Satta, Alessandro, et al.
Publicado: (2019)

Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
por: Barilà, Gregorio, et al.
Publicado: (2021)

Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy
por: Farhangnia, Pooya, et al.
Publicado: (2023)

Bispecific antibodies and their applications
por: Fan, Gaowei, et al.
Publicado: (2015)

The making of bispecific antibodies
por: Brinkmann, Ulrich, et al.
Publicado: (2017)

Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells
por: Urbanska, Katarzyna, et al.
Publicado: (2014)

State of the Art in Tumor Antigen and Biomarker Discovery
por: Even-Desrumeaux, Klervi, et al.
Publicado: (2011)

In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy
por: Kruse, Robert L., et al.
Publicado: (2017)

Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
por: Lin, Tsung-Yi, et al.
Publicado: (2021)

LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer
por: Qiao, Guilin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k7epglb3j4lc5gcjb4m1vi4eu4